Myriad Genetics Inc
) entered into a research collaboration with biotechnology
BioMarin Pharmaceutical Inc
). This is the second such arrangement forged between the two
partners. However, the terms of the agreement are yet to be
ACTELION LTD (ALIOF): Get Free Report
BIOMARIN PHARMA (BMRN): Free Stock Analysis
HESKA CORP (HSKA): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
To read this article on Zacks.com click here.
The recent agreement allows BioMarin to use Myriad's novel
Homologous Recombination Deficiency test, popularly known as HRD.
This test will help detect tumors that have lost the ability to
repair double-stranded DNA breaks, resulting in increased
susceptibility to DNA-damaging drugs. Tumors that could adversely
respond to BioMarin's drug candidate, BMN-673, can also be
identified through this test.
Myriad recognizes the complex and dynamic nature of the biology
of cancer. The joint initiative fulfils the need for a
comprehensive test to identify patients who can possibly benefit
from treatment with PARP inhibitors or DNA damaging agents.
Myriad Genetics develops new molecular diagnostic tests taking
into account the active role of genes in the treatment and
recurrence of diseases.
BMN 673 is a novel and highly potent PARP1/2 inhibitor used for
the treatment of human cancers with DNA repair deficiency.
PARP1/2 inhibitors comprise a class of anti-cancer agents that
target tumor-specific defects in DNA repair. Currently, BMN 673
is undergoing early-phase clinical development meant to evaluate
its success rate in cancer treatment.
Globally, medical as well as research professionals have been
constantly trying to formulate new ways and means to determine
the genetic causes of DNA repair deficiency in the treatment of
fatal diseases, such as cancer. The HRD test from Myriad promises
to overcome this problem by identifying patients who can benefit
from cancer therapy using BioMarin's PARP inhibitor BMN 673.
In Oct 2013, Myriad had forged its first agreement with BioMarin
to use its BRACAnalysis test in connection with the latter's
Phase III study of BMN-673 for breast cancer.
Currently, Myriad Genetics Inc. carries a Zacks Rank #2 (Buy).
Investors interested in the industry may consider stocks like
). All these stocks carry a #1 (Strong Buy).